Literature DB >> 3954934

The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone.

F J Frey, M K Rüegsegger, B M Frey.   

Abstract

An analysis of the literature was performed, revealing that in many studies both the desired and the undesired effects are decreased in alternate-day prednisone regimens as compared with the daily regimens. In the present report evidence is given that part of the diminished biological effect of dose-spacing regimens is attributable to a decreased total exposure to prednisolone. Following a high dose of 0.8 mg kg-1 of oral prednisone or prednisolone the plasma concentration vs time curves of total prednisolone, unbound prednisolone and prednisolone bound to albumin or transcortin were always less than four times higher than following a low dose of 0.2 mg kg-1 of prednisone or prednisolone. This dose-dependent systemic availability of prednisolone explains partly the diminished biological effect when the same total amount of prednisone or prednisolone is divided into several small doses as opposed to a single oral dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954934      PMCID: PMC1400906          DOI: 10.1111/j.1365-2125.1986.tb05173.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

1.  Alternate-day steroid regimen in the treatment of ocular disease.

Authors:  S Schutz; R Newhouse; J D Russo
Journal:  Br J Ophthalmol       Date:  1968-06       Impact factor: 4.638

2.  Adrenocortical responsiveness after alternate-day corticosteroid therapy.

Authors:  G L Ackerman; C M Nolsn
Journal:  N Engl J Med       Date:  1968-02-22       Impact factor: 91.245

3.  An evaluation of intermittent corticosteroid therapy in the management of ulcerative colitis.

Authors:  A E Cocco; A I Mendeloff
Journal:  Johns Hopkins Med J       Date:  1967-03

Review 4.  Transport of protein-bound hormones into tissues in vivo.

Authors:  W M Pardridge
Journal:  Endocr Rev       Date:  1981       Impact factor: 19.871

5.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

6.  Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma.

Authors:  F J Frey; B M Frey; L Z Benet
Journal:  Clin Chem       Date:  1979-11       Impact factor: 8.327

7.  Prednisolone clearance at steady state in dogs.

Authors:  F J Frey; B M Frey; A Greither; L Z Benet
Journal:  J Pharmacol Exp Ther       Date:  1980-11       Impact factor: 4.030

8.  Plasma protein-binding parameters of prednisolone in immune disease patients receiving long-term prednisone therapy.

Authors:  J G Wagner; D Wexler; I T Ağabeyoğlu; R F Bergstrom; E Sakmar; D R Kay
Journal:  J Lab Clin Med       Date:  1981-04

9.  Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study.

Authors:  J J Curtis; J H Galla; S Y Woodford; R J Saykaly; R G Luke
Journal:  Am J Kidney Dis       Date:  1981-11       Impact factor: 8.860

10.  Effect of prednisone dose spacing on plasma lipids.

Authors:  J H Galla; J J Curtis; S Y Woodford; E D Rees; G W Somes; R G Luke
Journal:  J Lab Clin Med       Date:  1980-06
View more
  8 in total

1.  Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man.

Authors:  J A Wald; R M Law; E A Ludwig; R R Sloan; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

Review 2.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Low dose prednisolone in nephrotic syndrome.

Authors:  I A Choonara; D Heney; S R Meadow
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

4.  Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Brett C McWhinney; Jacobus P J Ungerer; Gregory Medley; David W Johnson; Carmel M Hawley; Diana R Leary; Scott B Campbell; Christine E Staatz
Journal:  Eur J Clin Pharmacol       Date:  2011-06-09       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

6.  Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients.

Authors:  Troels K Bergmann; Nicole M Isbel; Remo Ostini; Katherine A Barraclough; Scott B Campbell; Brett C McWhinney; Warrick J Inder; Anthony Russell; Christine E Staatz
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

Review 7.  Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential.

Authors:  Valeria Ferrero; Flavio Ribichini; Gabriele Pesarini; Sandra Brunelleschi; Corrado Vassanelli
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma.

Authors:  J Xu; J Winkler; H Derendorf
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-02-23       Impact factor: 2.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.